| |
HCV- (n=224) |
HCV+ (n=84) |
P value |
| Age, yrs, median (IQR) |
45.0 (38.9, 51.5) |
53.1 (49.5, 56.6) |
<0.0001* |
| Race/ethnicity, n (%) |
|
|
0.22§ |
| White non-Hispanic |
40 (17.9) |
10 (11.9) |
|
| Black non-Hispanic |
143 (63.8) |
64 (76.2) |
|
| Hispanic |
27 (12.1) |
8 (9.5) |
|
| Other |
14 (6.2) |
2 (2.4) |
|
| Alcohol use, n (%) |
|
|
0.069# |
| Abstainer (no drinks) |
100 (44.6) |
39 (46.4) |
|
| Light (<3 drinks/week) |
61 (27.2) |
19 (22.6) |
|
| Moderate (3-13 drinks/week) |
35 (15.6) |
7 (8.3) |
|
| Heavier (≥14 drinks/week) |
24 (10.7) |
17 (20.2) |
|
| Smoker, n (%) |
|
|
<0.0001# |
| Never |
70 (31.3) |
8 (9.5) |
|
| Current |
84 (37.5) |
57 (67.9) |
|
| Former |
70 (31.3) |
19 (22.6) |
|
| Ever injected drug use, n (%) |
28 (12.5) |
67 (79.8) |
<0.0001# |
| BMI, median (IQR) |
25.6 (22.6, 28.7) |
25.7 (21.9, 28.8) |
0.83* |
| HIV status, n (%) |
|
|
0.020# |
| Positive |
167 (74.6) |
73 (86.9) |
|
| Negative |
57 (25.4) |
11 (13.1) |
|
| HCV RNA´103 IU/ml, median (IQR) |
/ |
2020 (651, 4020) |
/ |
| Ever HCV medication |
/ |
17 (20.2) |
/ |
| AST, IU/L, median (IQR) |
20 (16, 25) |
38.5 (28.5, 71.5) |
<0.0001* |
| ALT, IU/L, median (IQR) |
16 (11, 23) |
29 (20.5, 48) |
<0.0001* |
| Platelets, ´103/µl, median (IQR) |
237.5 (203, 280.5) |
193.5 (157.5, 228.5) |
<0.0001* |
| Platelets<150´103/µl, n (%) |
9 (4.0) |
20 (23.8) |
<0.0001# |
| Albumin (g/L) |
4.3 (4.1, 4.5) |
4.0 (3.7, 4.3) |
<0.0001* |
| HA, ng/mL, median (IQR) |
22 (12.5, 38) |
55.5 (31, 114) |
<0.0001* |
| SHASTA, median (IQR) |
0.02 (0.02, 0.02) |
0.11 (0.02, 0.41) |
<0.0001* |
| APRI, median (IQR) |
0.26 (0.20, 0.33) |
0.54 (0.38, 1.17) |
<0.0001* |
| METAVIR stage using TE cutpoints, n (%) |
|
|
<0.0001§ |
| F0-1 |
202 (90.2) |
45 (53.6) |
|
| F2 |
15 (6.7) |
13 (15.5) |
|
| F3 |
3 (1.3) |
10 (11.9) |
|
| F4 |
4 (1.8) |
16 (19.0) |
|
|
